Abstract 234P
Background
Cancer stem cells (CSCs) are a heterogeneous population of cancer cells with characteristics similar to normal stem cells, including the ability for self-renewal and differentiation. CSCs can differentiate into tumor-supporting cells potentially enabling metastasis, relapse, and chemoresistance. Complex networks involving several transcription factors, such as Nanog, Oct4, SOX2, and various miRNAs, have been identified to regulate CSC properties. The EMT is a process in which epithelial cells change their morphology, lose their polarity and acquire the migratory properties of mesenchymal cells. Many reports have shown that cells undergoing EMT can acquire stem cell-like characteristics and express markers of the EMT. However, the correlation between stemness and EMT is still unclear in oral squamous cell carcinomas.
Methods
Tumor tissues and adjacent clinically normal tissues were obtained from 50 patients with primary oral squamous cell carcinoma (OSCC) and 40 patients with recurrent OSCC. The expression of CSC markers Nanog, SOX2, and OCT4 and EMT markers SLUG and TWIST-1 were analyzed using immunohistochemistry. The mean immunoreactive score (staining intensity x proportion of positive cells) was calculated and compared in both tumor tissue and adjacent tissue. The immunohistochemical expression of these markers was correlated with pathological grade, lymph node metastasis, and AJCC staging of the tumor. Additionally, the expressions of SOX-2 and SLUG were evaluated in human OSCC cell lines using Western blot.
Results
The mean immunoreactive score of Nanog, SOX2, OCT4, SLUG and TWIST-1was higher in tumor tissues compared to adjacent tissue. Likewise, higher expression of both CSC and EMT markers was noted in recurrent OSCC than primary OSCC. High-grade tumors and those showing lymph node metastasis exhibited significantly increased expression of SOX-2, OCT4, and SLUG (p<0.01). Western blot analysis showed higher expression of SOX-2 and SLUG proteins in OSCC cells. Knockdown of SOX-2 and SLUG inhibited the migration and invasion of OSCC cells as demonstrated using transmigration assay.
Conclusions
The present study provides novel insights into the potential association between CSCs and EMT in OSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03